P/E at 35.48 vs Industry's 34.18: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Parity

The current P/E of 35.48 for Sun Pharmaceutical Industries Ltd sits just above the sector average of 34.18, indicating a valuation premium of roughly 3.8%. This premium is relatively modest compared to some large-cap peers in the pharmaceuticals space, suggesting that the market is pricing in steady earnings growth or a degree of resilience. The sector itself is characterised by a broad range of valuations, with some companies trading at significant discounts or premiums depending on their pipeline, regulatory environment, and global exposure. The premium here may reflect Sun Pharma’s established market position and diversified portfolio, but it also raises questions about whether the current price fully accounts for emerging challenges in the sector — previously rated Strong Buy, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns reveals a divergence between short-term and longer-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a positive return of 8.52%, significantly outperforming the Sensex’s decline of 6.77%. This outperformance extends to the three-month horizon, where the stock gained 6.13% compared to the Sensex’s 6.37% loss. However, the most recent week and day show a slight underperformance, with the stock down 0.03% and 0.02% respectively, while the Sensex gained 0.92% and 0.32%. This suggests a recent pause or consolidation phase after a period of relative strength. The one-month return of 3.70% versus the Sensex’s negative 1.79% further confirms the stock’s resilience over the medium term — is this a temporary correction or a sign of shifting investor sentiment?

Moving Average Configuration: Signs of a Consolidation Phase

The technical setup for Sun Pharmaceutical Industries Ltd reveals a nuanced trend. The stock is trading above its 50-day, 100-day, and 200-day moving averages, signalling that the medium to long-term trend remains intact and positive. However, it is currently below its 5-day and 20-day moving averages, indicating some short-term weakness or consolidation. This configuration often suggests a pause or minor pullback within a broader uptrend, rather than a full reversal. The stock is also trading just 4% below its 52-week high of Rs 1917.15, which points to a relatively strong price level maintained over the past year. The 5-day and 20-day moving averages acting as resistance could be a short-term hurdle — is this a genuine recovery or a dead-cat bounce? — the moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Performance

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent quarters. Out of 24 stocks that have declared results, 15 reported positive outcomes, 6 were flat, and 3 posted negative results. This overall positive skew supports the sector’s resilience despite regulatory pressures and pricing challenges. Sun Pharmaceutical Industries Ltd’s performance aligns with this trend, showing steady gains and relative strength. The sector’s average P/E of 34.18 reflects a balanced valuation environment, with investors differentiating between companies based on pipeline strength, global footprint, and cost efficiencies. The sector’s mixed results raise the question — how will Sun Pharma navigate the evolving industry dynamics?

Rating Context: Previously Strong Buy, Now Reassessed

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Strong Buy. The rating was updated on 18 May 2026, reflecting a reassessment of the stock’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the change indicates a fresh evaluation of the company’s prospects in light of recent performance and market conditions. The stock’s Mojo Score stands at 74.0, consistent with a large-cap stock maintaining solid fundamentals. The reassessment invites investors to consider the balance between valuation premium and recent momentum — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Valuation with Mixed Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight premium to its sector, supported by solid one-year and medium-term returns. The recent short-term underperformance and technical setup below the 5-day and 20-day moving averages suggest a phase of consolidation rather than a breakdown. The sector’s overall positive results provide a supportive backdrop, though the reassessment of the rating signals a need for investors to weigh valuation against momentum carefully. The stock’s proximity to its 52-week high further underscores its resilience in a competitive industry environment — what is the current rating for Sun Pharmaceutical Industries Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today